Search This Blog

Monday, June 23, 2025

Merck Phase 3 of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Pulmonary Arterial Hypertension

 

  • Merck's Phase 3 HYPERION study of WINREVAIR™ shows positive results for pulmonary arterial hypertension (PAH) treatment.
  • WINREVAIR significantly reduces the risk of clinical worsening in PAH patients, with a notable impact among those on double background therapy.
  • HYPERION study results to be presented at a future medical meeting, with regulatory submissions forthcoming.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.